Drug Trial Radar · NCT05372614
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Oct 5, 2022
Primary completion
Jul 17, 2028
Study completion Jul 17, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- May 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Adding neratinib to trastuzumab deruxtecan may be able to shrink cancer with a change in the HER2 gene.
Conditions
- Metastatic Malignant Solid Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Malignant Solid Neoplasm
- Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
Echocardiography TestProcedure
Undergo echocardiography
Multigated Acquisition ScanProcedure
Undergo MUGA scan
Neratinib MaleateDrug
Given PO
Trastuzumab DeruxtecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (Part 1, Dose Escalation)Time frame: In the first 2 cycles in dose escalation of combination of neratinib and trastuzumab deruxtecan (DS-8201a) (cycle length = 21 days)
- Incidence of treatment-emergent adverse events (Part 1, Dose Escalation)Time frame: In the first 2 cycles of combination of neratinib and DS-8201a (cycle length = 21 days)
- Objective response rate (ORR) (Part 2, Pancreatic Cohort)Time frame: Up to 1 year
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Suspended
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
City of Hope South Pasadena
South Pasadena, California · Suspended
City of Hope Upland
Upland, California · Suspended
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Suspended
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin · Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.